RecruitingPhase 4NCT03976245

Advanced Therapeutics in Rheumatoid Arthritis (RA)

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Enrollment

144 participants

Start Date

Mar 1, 2020

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis

Summary

This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how well advanced treatments (biologics or JAK inhibitors) work in patients with severe rheumatoid arthritis (RA) who have already tried and failed multiple standard medications. **You may be eligible if...** - You are 18 or older and have rheumatoid arthritis - You have 5 or more swollen joints - Your RA has failed treatment with methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide - You are seropositive (your blood tests positive for RA markers) and have bone erosions - You have not previously used a biologic or JAK inhibitor **You may NOT be eligible if...** - You have an active serious infection or active tuberculosis - You have multiple sclerosis, current or prior lymphoma, or current cancer - You have a contraindication to etanercept or tofacitinib - You are under 18 or unable to consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.